{"id":"200207410672-48","name":"Stallergenes SAS","registrationDate":"2013-02-22T15:03:56.746+01:00","category":2,"subCategory":3,"legal":"A French simplified joint stock company with a capital of 13.893.505 euros","web":"http://www.stallergenesgreer.com","country":"France","headAddress":"6, rue Alexis de Tocqueville","headCity":"ANTONY CEDEX","headPostCode":"92183","headPhone":"(33)1 55 59 20 00","boss":"Michele ANTONELLI","bossTitle":"Mr","bossPosition":"President","membersCount":1,"membersFTE":"0.25","membership":"EBE (European Biopharmaceutical Enterprises)&#xd;\nLEEM (Les Entreprises du MÃ©dicament)","memberOrga":"","goal":"Dedicated to the research and development of innovative treatments of allergies and adopts a comprehensive approach to adressing and managing allergic diseases.","acronym":"","interests":"Environment, Public Health, Research and Technology","euInitiatives":"The reflection process on chronic diseases&#xd;<br />http://ec.europa.eu/health/major_chronic_diseases/reflection_process/index_en.htm&#xd;<br />&#xd;<br />Horizon 2020&#xd;<br />http://www.horizon2020.gouv.fr/&#xd;<br />&#xd;<br />EMA Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic &#xd;<br />diseases&#xd;<br />Doc. Ref. CHMP/EWP/18504/2006","lastUp":"2017-03-22T23:53:23.546+01:00","customers":"","costAbsolu":"","costRange":"0-9999","turnoverAbsolu":0,"turnoverRange":""}